Trials / Completed
CompletedNCT04180176
Prospective Clinicogenomic Program
A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 945 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood Draw | Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy. |
Timeline
- Start date
- 2019-12-13
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2019-11-27
- Last updated
- 2024-01-17
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04180176. Inclusion in this directory is not an endorsement.